Pohjois-Pohjanmaan hyvinvointialue

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Childhood cancers11 trials
• Acute lymphoblastic leukaemia3 trials
• Acute myeloid leukaemia3 trials
• Ovarian cancer2 trials
• Prostate cancer2 trials
• Sarcoma2 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
• Coronary artery disease1 trial
• Diffuse large B-cell lymphoma1 trial
• Endometrial cancer1 trial
• Follicular lymphoma1 trial
• Idiopathic pulmonary fibrosis1 trial
• and 2 more

Phase

• Phase 317 trials
• Phase 23 trials
• Phase 2/32 trials
• Phase 1/21 trial

Status

• Recruiting10 trials
• Completed5 trials
• Not yet recruiting5 trials
• Active, not recruiting3 trials

Lead sponsor

• Gustave Roussy, Cancer Campus, Grand Paris2 trials
• Stichting Hemato-Oncologie voor Volwassenen Nederland2 trials
• Amgen1 trial
• argenx1 trial
• AstraZeneca1 trial
• and 16 more

Running trials

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Ukonmaanaho Elli-Maija

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Genmab A/S· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.

  2024-510578-25-00· Phase 3· The University Of Birmingham· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· University of Birmingham· Source

• Recruiting

  A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  NCT04307576· Phase 3· Mats Heyman· Source

• Recruiting

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· Phase 2/3· Celgene· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· Phase 3· Pfizer· Source

• Active, not recruiting

  International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

  NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source

• Recruiting

  NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years

  NCT01828489· Phase 3· Vaestra Goetalandsregionen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers9 recruiting
• Acute myeloid leukaemia3 recruiting
• Sarcoma2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Endometrial cancer1 recruiting
• Ovarian cancer1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

  NCT04844866· Phase 2· Miltenyi Biomedicine GmbH· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Active, not recruiting

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· Phase 3· AstraZeneca· Source

• Recruiting

  International Study for Treatment of High Risk Childhood Relapsed ALL 2010

  NCT03590171· Phase 2· Charite University, Berlin, Germany· Source